Paloma Partners Management Co Takes $152,000 Position in Strongbridge Biopharma plc (SBBP)

Paloma Partners Management Co acquired a new stake in Strongbridge Biopharma plc (NASDAQ:SBBP) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 20,922 shares of the biotechnology company’s stock, valued at approximately $152,000. Paloma Partners Management Co owned approximately 0.05% of Strongbridge Biopharma as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Caxton Corp increased its position in shares of Strongbridge Biopharma by 2.2% in the 3rd quarter. Caxton Corp now owns 5,514,994 shares of the biotechnology company’s stock valued at $38,053,000 after buying an additional 120,000 shares in the last quarter. Broadfin Capital LLC increased its position in shares of Strongbridge Biopharma by 10.4% in the 4th quarter. Broadfin Capital LLC now owns 3,186,695 shares of the biotechnology company’s stock valued at $23,104,000 after buying an additional 299,900 shares in the last quarter. Armistice Capital LLC increased its position in shares of Strongbridge Biopharma by 69.4% in the 4th quarter. Armistice Capital LLC now owns 2,870,000 shares of the biotechnology company’s stock valued at $20,808,000 after buying an additional 1,175,400 shares in the last quarter. BlackRock Inc. increased its position in shares of Strongbridge Biopharma by 57.5% in the 4th quarter. BlackRock Inc. now owns 1,432,365 shares of the biotechnology company’s stock valued at $10,385,000 after buying an additional 522,875 shares in the last quarter. Finally, Opaleye Management Inc. increased its position in shares of Strongbridge Biopharma by 5.9% in the 4th quarter. Opaleye Management Inc. now owns 1,250,000 shares of the biotechnology company’s stock valued at $9,062,000 after buying an additional 70,000 shares in the last quarter. Institutional investors and hedge funds own 57.63% of the company’s stock.

How to Become a New Pot Stock Millionaire

SBBP has been the subject of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on shares of Strongbridge Biopharma in a research report on Tuesday, December 5th. They issued a “buy” rating and a $14.00 price objective for the company. Zacks Investment Research lowered shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Friday, March 16th. BidaskClub lowered shares of Strongbridge Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a research note on Thursday, January 18th. Two equities research analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. Strongbridge Biopharma presently has a consensus rating of “Buy” and an average target price of $12.81.

Shares of NASDAQ SBBP opened at $8.85 on Friday. The firm has a market capitalization of $402.75, a P/E ratio of -6.10 and a beta of 1.49. The company has a debt-to-equity ratio of -3.17, a current ratio of 4.88 and a quick ratio of 4.84. Strongbridge Biopharma plc has a 1-year low of $3.50 and a 1-year high of $9.02.

WARNING: This piece was first published by WKRB News and is the property of of WKRB News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/03/31/paloma-partners-management-co-takes-152000-position-in-strongbridge-biopharma-plc-sbbp.html.

Strongbridge Biopharma Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Want to see what other hedge funds are holding SBBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Strongbridge Biopharma plc (NASDAQ:SBBP).

Institutional Ownership by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply